The Journal of Immunology · 2005 · 151 citations · 21 references
MedicineCancer BiologyOncologyCarcinogenesisMolecular OncologyOncogenesCancer Cell SignalingCancer ProgressionMalignant NeoplasmsOncogenic Signaling PathwaysSignal Transduction In CancerTumor BiologyApoptosis Signaling In CancerCell Death In CancerP53 InactivationSpontaneous Animal Tumor ModelsSpontaneous Tumor ModelsTrail ReceptorsTrail-mediated ApoptosisTumor Suppressor Pathways
TNF apoptosis-inducing ligand is attracting considerable interest as a potential extrinsic tumor suppressor mechanism, although previous reports have conveyed somewhat contrasting views regarding the likely importance of this pathway. In this study, we provide the first evaluation of spontaneous tumor formation over the life span of TRAIL-deficient mice. Interestingly, >25% of these mice do develop lymphoid malignancies after 500 days of life. TRAIL suppressed the initiation and development of both tumors of lymphoid and stromal origin in the context of the loss of at least one p53 allele. Specific examination of the role of TRAIL in Her2/neu oncogene-driven mammary epithelial cancer revealed no critical role for TRAIL despite the inherent TRAIL sensitivity of such mammary carcinomas. Overall, the data indicate an important function of TRAIL in controlling carcinogenesis, but suggest that further examination of this pathway in epithelial malignancies is warranted.
21
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Lawrence A. Donehower, Michele Harvey, Betty L. Slagle et al. · Nature · 1992 · 4.7K citations
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Mark J. Smyth, Kevin Thia, Shayna E.A. Street et al. · The Journal of Experimental Medicine · 2000 · 803 citations · Full text
Life Sciences, Immunology, Oncology +15